Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. This Specialist Protein company focuses on research, development, manufacture and distribution of innovative immuno-diagnostic systems and assays for the global laboratory market.

Based in Birmingham, UK where their products are manufactured, Binding Site supports sales in North America and most of Europe through its 8 offices and by a distributor network in over 80 other countries. Worldwide the company employs around 600 people with over 400 based in Birmingham. Since April 2011 Binding Site has been owned by Nordic Capital Fund VII. With the strategic and financial support of Nordic Capital, Binding Site is further strengthening its position as the world’s leading supplier of IVD systems for identifying and monitoring B-cell dyscrasias and primary immunodeficiency. Turnover for the year to September 2012 was approximately £55 million, an increase of 15% on the previous year[HW1] .

Binding Site manufactures a wide range of high quality innovative products: OEM. Our experience and expertise in the in-vitro diagnostics market means we can supply the high quality materials, specialist technical support, excellent customer service, bespoke products, reliability and problem-solving approach that our OEM partners need. Freelite® is a novel and highly significant tumour marker used for the diagnosis, prognosis and monitoring of Multiple Myeloma, a cancer of cells in the bone marrow. Hevylite®, a new tumour marker complementary to Freelite , is providing clinicians with further information to manage patients with Multiple Myeloma. Primary Immunodeficiency Diseases (PID).